Covid-19 roundup: EMA starts re­view of SK’s vac­cine; Aus­tralian biotech switch­ing gears away from Covid re­search

An­oth­er Covid-19 vac­cine will en­ter the fray as the EMA kicks off its con­di­tion­al mar­ket­ing au­tho­riza­tion ap­pli­ca­tion for SK’s vac­cine, dubbed Sky­covion.

SK Chem­i­cals GmbH sub­mit­ted da­ta to the EMA on how well the vac­cine trig­gers the pro­duc­tion of an­ti­bod­ies against the orig­i­nal strain of SARS-CoV-2, along with da­ta on the safe­ty and qual­i­ty of the vac­cine.

“The eval­u­a­tion of Sky­covion is one of the on­go­ing eval­u­a­tions of da­ta on Covid-19 vac­cines. As the pan­dem­ic con­tin­ues to evolve, it is im­por­tant that the EU has a wide ar­ray of vac­cines and treat­ments to en­able the Mem­ber States to com­bat the pan­dem­ic ef­fec­tive­ly. EMA and its sci­en­tif­ic com­mit­tees are com­mit­ted to en­sur­ing a ro­bust re­view of all da­ta on COVID-19 vac­cines and med­i­cines,” the EMA said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER